Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area

Shibata, Shoyo; Uemura, Ryotaro; Suzuki, Takeshi

doi:10.1177/2168479015600205

Cited by 18 publications

(19 citation statements)

References 19 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we reported that the reward system unique to Japan has had a positive effect on drug sales in specific therapeutic areas, such as N and L drugs, indicating that the government has encouraging the development of these drugs. 20 The R 2 values for France and Germany suggest that these markets are also transitioning to a global market, and that they are currently at a more advanced stage than Japan (Figure 3). However, it is notable that the United Kingdom, Germany, and France, which have less market share than Japan (Table 1), are closer to a global market.…”

Section: Discussionmentioning

confidence: 96%

Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany

Shibata

Uemura

Suzuki

2016

Ther Innov Regul Sci

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany

Shibata

Uemura

Suzuki

2016

Ther Innov Regul Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ''NHI Drug Price Premium for Promoting the Creation of New Drugs and the Elimination of Offlabel Use'' is a price addition within the Japanese NHI drug pricing system. [19][20][21] This price addition is targeted at medicines whose price divergence rates (ratio of delivery price to official price) are lower than average (across all medicines). The medicines for which such a price addition are received are targeted for a special price reduction by the government in the drug price revision after the first generic medicine enters the market.…”

Section: Analysis Of Sales After Generic Entrymentioning

confidence: 99%

Impact of generic entry to off-patent branded medicines in Japanese pharmaceutical market

Fukumoto

Suzuki

2017

Journal of Generic Medicines

Self Cite

View full text Add to dashboard Cite

The Japanese pharmaceutical market is known for having a relatively low market penetration of generic medicines. However, the velocity of generic penetration varies among medicines. Looking at current sales and share of off-patent branded medicines and generic medicines in Japanese pharmaceutical market, our main aim is to identify the factors associated with sales reductions of off-patent medicines and price competition caused by generic entry in the Japanese pharmaceutical market. We showed as one result that an increase in the number of generic maker entries significantly increases both price competition and sales reductions of off-patent branded medicines. As a second factor of note, we found that being subject to ''NHI Drug Price Premium for Promoting the Creation of New Drugs and the Elimination of Off-label Use'' before generic entry is related to maintaining sales of off-patent branded medicines after generic entry. The importance of generic medicines is increasing in association with the hypertrophy of health care expenditures in Japan. Efficient polices and corporate strategies reflecting market principles are strongly needed. Detailed results of this study on what determines whether sales and prices of off-patent medicines significantly decrease after generic entry in the Japanese pharmaceutical market should be useful for this purpose.

show abstract

“…The share of cardiovascular system drugs is relatively high among the top 100 drugs in the Japanese market, while that of antineoplastic and immunomodulating agents is relatively low. 3 Because the Japanese drug pricing system has encouraged R&D of new antineoplastic and immunomodulating agents and nervous system drugs that are likely to sell well in the Western market as well as the Japanese market, [4][5][6] the Japanese pharmaceutical market for these drugs is regarded as becoming similar to the markets of Western countries. 2 However, because the research focus on new molecular entities (NMEs) in Japan is limited, it is essential to discuss the prognosis of the Japanese pharmaceutical market.…”

Section: Introductionmentioning

confidence: 99%

Analysis of new molecular entity trends from 2006 to 2015 in Japan

Shibata

Fukumoto

Ozaki

et al. 2020

Journal of Generic Medicines

Self Cite

View full text Add to dashboard Cite

Japan is one of the largest pharmaceutical markets in the world, and as such, pharmaceutical companies are intensively conducting research and development of new drugs in Japan. However, information on Japanese pharmaceutical market profiles is limited. In this context, we elucidated the market characteristics and trends of new molecular entities approved between 2006 and 2015 in Japan. Among antineoplastic and immunomodulating agents, the highest number was first approved in the United States, and for nervous system drugs, the highest number was first approved in Europe. The alimentary tract and metabolism and the musculoskeletal system were the therapeutic areas for which the most drugs were approved for the first time in Japan. Most of the musculoskeletal system drugs were developed by Japanese companies, and most of the antineoplastic and immunomodulating agents were developed outside of Japan. Using various performance indexes, such as market forecasts and significance of clinical benefits, we determined that the number of new molecular entities and market size increased and the number of drugs with significant clinical benefits decreased. These results suggest that new molecular entity innovation by Japanese companies has been decreasing and the government’s comparative method for pricing does not work well in Japan.

show abstract

Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area

Abstract: Our study suggests that this system has been working according to its original aim of promoting the development of innovative drugs in Japan.

Cited by 18 publications

References 19 publications

Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany

Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany

Impact of generic entry to off-patent branded medicines in Japanese pharmaceutical market

Analysis of new molecular entity trends from 2006 to 2015 in Japan

Contact Info

Product

Resources

About